These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25162219)

  • 41. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
    Odani A; Hashimoto Y; Otsuki Y; Uwai Y; Hattori H; Furusho K; Inui K
    Clin Pharmacol Ther; 1997 Sep; 62(3):287-92. PubMed ID: 9333104
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Population Pharmacokinetics of Phenytoin Based on NONMEM in Patients with Intracranial Tumor During the First Week of Post-Craniotomy.
    Li ZD; Liu M; Li L; Wan JH; Lei Z; Huang YA
    Curr Drug Metab; 2016; 17(7):721-8. PubMed ID: 27174459
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene-gene interactions on warfarin therapy.
    Khalighi K; Cheng G; Mirabbasi S; Khalighi B; Wu Y; Fan W
    J Thromb Thrombolysis; 2017 Jan; 43(1):124-129. PubMed ID: 27743182
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance.
    Kousar S; Wafai ZA; Wani MA; Jan TR; Andrabi KI
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):504-16. PubMed ID: 25943175
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
    Chang WC; Hung SI; Carleton BC; Chung WH
    Expert Opin Drug Metab Toxicol; 2020 Aug; 16(8):723-734. PubMed ID: 32510242
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy.
    Ahn JE; Cloyd JC; Brundage RC; Marino SE; Conway JM; Ramsay RE; White JR; Musib LC; Rarick JO; Birnbaum AK; Leppik IE
    Neurology; 2008 Jul; 71(1):38-43. PubMed ID: 18591503
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of genetic polymorphisms of cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on drug-resistant epilepsy in Turkish children.
    Seven M; Batar B; Unal S; Yesil G; Yuksel A; Guven M
    Mol Diagn Ther; 2014 Apr; 18(2):229-36. PubMed ID: 24338437
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes and phenytoin adverse reactions correlation.
    Twardowschy CA; Werneck LC; Scola RH; De Paola L; Silvado CE
    Arq Neuropsiquiatr; 2011 Apr; 69(2A):153-8. PubMed ID: 21537551
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A real-life pilot study of the clinical application of pharmacogenomics testing on saliva in epilepsy.
    Riva A; Roberti R; D'Onofrio G; Vari MS; Amadori E; De Giorgis V; Cerminara C; Specchio N; Pietrafusa N; Tombini M; Assenza G; Cappanera S; Marini C; Rasmini P; Veggiotti P; Zara F; Russo E; Striano P
    Epilepsia Open; 2023 Sep; 8(3):1142-1150. PubMed ID: 36840436
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India.
    Rosemary J; Surendiran A; Rajan S; Shashindran CH; Adithan C
    Indian J Med Res; 2006 May; 123(5):665-70. PubMed ID: 16873909
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vivo binding characteristics of phenytoin to serum proteins in monotherapy pediatric patients with epilepsy.
    Kodama H; Kodama Y; Shinozawa S; Kanemaru R; Itokazu N; Sugimoto T
    Int J Clin Pharmacol Ther; 2000 Jan; 38(1):25-9. PubMed ID: 10667833
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Evolution of Population Pharmacokinetic Model of Oral Phenytoin for Early Seizure Prophylaxis Post-Craniotomy.
    Li Z; Wang C; Ji S; Jin H; Song G
    Curr Drug Metab; 2019; 20(9):756-764. PubMed ID: 31518217
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phenobarbital-induced severe cutaneous adverse drug reactions are associated with CYP2C19*2 in Thai children.
    Manuyakorn W; Siripool K; Kamchaisatian W; Pakakasama S; Visudtibhan A; Vilaiyuk S; Rujirawat T; Benjaponpitak S
    Pediatr Allergy Immunol; 2013 May; 24(3):299-303. PubMed ID: 23551241
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relevance of the ancestry for the variability of the Drug-Metabolizing Enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population.
    Céspedes-Garro C; Rodrigues-Soares F; Jiménez-Arce G; Naranjo MG; Tarazona-Santos E; Fariñas H; Barrantes R; Llerena A;
    Rev Biol Trop; 2016 Sep; 64(3):1067-76. PubMed ID: 29461783
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
    Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
    J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The relationship between phenytoin pharmacokinetics and the CYP2C19 genotype in Japanese epileptic patients.
    Watanabe M; Iwahashi K; Kugoh T; Suwaki H
    Clin Neuropharmacol; 1998; 21(2):122-6. PubMed ID: 9579299
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.
    Naranjo MG; Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Fariñas H; Rodeiro I; Terán E; Grazina M; Moya GE; López-López M; Sarmiento AP; Calzadilla LR; Ramírez-Roa R; Ortiz-López R; Estévez-Carrizo FE; Sosa-Macías M; Barrantes R; LLerena A;
    OMICS; 2018 Sep; 22(9):575-588. PubMed ID: 30183544
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of CYP2C9 polymorphisms with phenytoin toxicity in Indian patients.
    Thakkar AN; Bendkhale SR; Taur SR; Gogtay NJ; Thatte UM
    Neurol India; 2012; 60(6):577-80. PubMed ID: 23287317
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.
    Scordo MG; Pengo V; Spina E; Dahl ML; Gusella M; Padrini R
    Clin Pharmacol Ther; 2002 Dec; 72(6):702-10. PubMed ID: 12496751
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population.
    Afilal D; Basselam MA; Brakez Z; Chouham S; Brehm A; Izaabel EH
    Genet Test Mol Biomarkers; 2017 May; 21(5):298-304. PubMed ID: 28282224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.